AU2001278139A1 - Enhanced replication of hcv rna - Google Patents

Enhanced replication of hcv rna

Info

Publication number
AU2001278139A1
AU2001278139A1 AU2001278139A AU7813901A AU2001278139A1 AU 2001278139 A1 AU2001278139 A1 AU 2001278139A1 AU 2001278139 A AU2001278139 A AU 2001278139A AU 7813901 A AU7813901 A AU 7813901A AU 2001278139 A1 AU2001278139 A1 AU 2001278139A1
Authority
AU
Australia
Prior art keywords
hcv rna
provides methods
enhanced replication
cells
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278139A
Inventor
Hui-Hua Lu
Mark Selby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001278139A1 publication Critical patent/AU2001278139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This invention provides methods of generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and that stably replicate HCV sub-genomic replicons. The invention also provides methods of using the cells of the invention to screen for compounds that modulate viral RNA replication, including HCV RNA replication.
AU2001278139A 2000-08-04 2001-08-03 Enhanced replication of hcv rna Abandoned AU2001278139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22324400P 2000-08-04 2000-08-04
US60/223,244 2000-08-04
PCT/US2001/024276 WO2002012477A2 (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna

Publications (1)

Publication Number Publication Date
AU2001278139A1 true AU2001278139A1 (en) 2002-02-18

Family

ID=22835673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278139A Abandoned AU2001278139A1 (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna

Country Status (7)

Country Link
US (2) US6660471B2 (en)
EP (1) EP1320583B1 (en)
AT (1) ATE318893T1 (en)
AU (1) AU2001278139A1 (en)
CA (1) CA2416633C (en)
DE (1) DE60117561T2 (en)
WO (1) WO2002012477A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4299540B2 (en) * 2001-01-23 2009-07-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Hepatitis C virus replicon and replicon enhanced cells
WO2003085084A2 (en) * 2002-04-03 2003-10-16 Smithkline Beecham Corporation Hepatitis c virus sub-genomic replicons
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6740519B1 (en) * 1997-11-03 2004-05-25 Mount Sinai School Of Medicine Immortalized, homozygous stat1-deficient mammalian cell lines and their uses

Also Published As

Publication number Publication date
DE60117561D1 (en) 2006-04-27
EP1320583B1 (en) 2006-03-01
US7183107B2 (en) 2007-02-27
WO2002012477A2 (en) 2002-02-14
CA2416633C (en) 2013-04-30
US20040076612A1 (en) 2004-04-22
DE60117561T2 (en) 2007-01-11
WO2002012477A3 (en) 2003-04-10
US20020142455A1 (en) 2002-10-03
CA2416633A1 (en) 2002-02-14
US6660471B2 (en) 2003-12-09
EP1320583A2 (en) 2003-06-25
ATE318893T1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE472335T1 (en) CHIMERE ALPHAVIRUS REPLICON PARTICLES
HK1125360A1 (en) Compounds and methods for inhibiting hepatitis c viral replication
HK1009980A1 (en) Method for selective inactivation of viral replication
IL162728A0 (en) Methods of inducing differentiationin stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem c
DK1021547T3 (en) Vaccine formulations containing papilloma virus capsomes and methods for their use
DK1820853T3 (en) Recombinant influenza virus for vaccines and gene therapy
MY140539A (en) 1-amino 1h-imidazoquinolines
RS20120201A2 (en) Methods and compositions for hepatitis c virus treatment
HUP0302957A2 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
UA85536C2 (en) Viral antigens
ATE508635T1 (en) VIRUS VECTORS AND THEIR USE IN THERAPEUTIC METHODS
MXPA05000655A (en) Methods and compositions for modulating t helper (th.
WO2003103571A3 (en) Flavivirus vaccines
NO20011162L (en) Methods and preparations for modulating the interaction of the APJ receptor with the HIV virus
DK1047446T3 (en) Vaccine composition for Herpes Simplex virus and methods for its use
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
AU2001278139A1 (en) Enhanced replication of hcv rna
MX9708679A (en) Soluble, cleavable substrates of the hepatitis c virus protease.
DK0906443T3 (en) Generation of replicating molecules in vivo
WO2004044182A3 (en) Highly permissive cell lines for hepatitis c virus replication
MXPA02012593A (en) Bvdv virus-like particles.
TR200201954T2 (en) Medicinal substances for viral diseases.
FI20020375A0 (en) Method for generating virus-like particles (VKP), plasmid construct and uses of the method
ATE263234T1 (en) MODIFIED SMALL RNA VIRUSES
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus